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Lactobacillus fermentum UCO-979C, a strain isolated from a human stomach, was
previously characterized by its potential probiotic properties. The UCO-979C strain
displayed the ability to beneficially regulate the innate immune response triggered by
Helicobacter pylori infection in human gastric epithelial cells. In this work, we conducted
further in vitro studies in intestinal epithelial cells (IECs) and in vivo experiments in
mice in order to characterize the potential immunomodulatory effects of L. fermentum
UCO-979C on the intestinal mucosa. Results demonstrated that the UCO-979C strain
is capable to differentially modulate the immune response of IECs triggered by Toll-
like receptor 4 (TLR4) activation through the modulation of TLR negative regulators’
expression. In addition, we demonstrated for the first time that L. fermentum UCO-979C
is able to exert its immunomodulatory effect in the intestinal mucosa in vivo. The feeding
of mice with L. fermentum UCO-979C significantly increased the production of intestinal
IFN-γ, stimulated intestinal and peritoneal macrophages and increased the number of
Peyer’s patches CD4+ T cells. In addition, L. fermentumUCO-979C augmented intestinal
IL-6, reduced the number of immature B220+CD24high B cells from Peyer’s patches,
enhanced the number of mature B B220+CD24low cells, and significantly increased
intestinal IgA content. The results of this work revealed that L. fermentum UCO-979C
has several characteristics making it an excellent candidate for the development of
immunobiotic functional foods aimed to differentially regulate immune responses against
gastric and intestinal pathogens.
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INTRODUCTION
It is widely recognized that commensal microorganisms are
relevant for human and animals health, participating in several
important biological functions including nutrients digestion,
vitamins synthesis, and pathogens inhibition (1, 2). The
importance of beneficial microorganisms of the microbiota in
the maintenance of immune health was also demonstrated in a
convincing way (3, 4). Several effective tools have already been
developed in order to study and manipulate the microbiota,
improve their beneficial properties for the host, and protect
against immune-related diseases (5, 6). In this regard, the
development of immunomodulatory probiotic (immunobiotic)
interventions offers opportunities for the modulation of the
mucosal immune system toward long lasting health (7).
The beneficial role of immunobiotic lactic acid bacteria (LAB)
has been extensively reported, supporting their implementation
to improve some immunological functions in the host (8–
10). The beneficial effect of immunobiotics on the immune
system occurs through direct and indirect interactions of
bacteria with immune and non-immune cells (11–14), leading
to cells’ activation and proliferation, cytokines production, IgA
secretion, antimicrobial peptides synthesis, and tight junctions
improvement (2, 11–14). Several research works including recent
transcriptomic analysis revealed that the immunomodulatory
effect of immunobiotics is a strain-specific characteristic (2, 12,
15), and therefore, each individual strain has to be studied in
detail in order to explore its immunomodulatory potential.
Immunobiotics has been proposed as an alternative to
prevent bacterial and viral infections in gastrointestinal
tract (10). Experimental models have demonstrated that
immunobiotics can attenuate the severity of infections caused by
several gastrointestinal pathogens including Helicobacter pylori,
Citrobacter rodentium, Listeria monocytogenes, and Salmonella
typhimurium (16). In this regard, it was reported that some
Lactobacillus strains are able to increase the resistance against
the gastric pathogenH. pylori. Among the mechanisms proposed
to explain the beneficial effects of probiotic lactobacilli are
the production of antimicrobial compounds, the inhibition
of pathogen’s adhesion and the modulation of the immune
system (17–19). We previously isolated Lactobacillus fermentum
UCO-979C from a human stomach sample and characterized
its potential probiotic properties (20, 21). We observed that
this strain is able to efficiently adhere to the gastric mucosa
as demonstrated by in vitro experiments in human gastric
adenocarcinoma cell-line (AGS cells) and in vivo studies in
Mongolian gerbils (21). L. fermentum UCO-979C also showed
the ability to strongly inhibit the adhesion, growth and urease
activity of H. pylori (21, 22). Moreover, we recently reported that
the UCO-979C strain beneficially modulates the innate immune
response triggered by H. pylori infection in human gastric
epithelial cells and macrophages (23). Our data showed reduced
levels of the pro-inflammatory factors IL-8, TNF-α, IL-1β, IL-6,
and MCP-1 expressions in L. fermentum UCO-979C-treated
AGS cells when compared to untreated infected controls. In
addition, improved production of the regulatory cytokine TGF-β
in response to H. pylori infection was detected in L. fermentum
UCO-979C-treated AGS cells (23). Interestingly, L. fermentum
UCO-979C was also capable of reducing the production of
TNF-α and improving IFN-γ and IL-10 levels in macrophages
challenged with H. pylori (23).
Taking into consideration the effect of L. fermentum UCO-
979C on the gastric immune response againstH. pylori infection,
we wonder whether this probiotic Lactobacillus strain is also able
to modulate immune responses in the intestinal tract. Therefore,
we conducted in vitro studies in intestinal epithelial cells (IECs)
and in vivo experiments in mice in order to characterize the
immunomodulatory effects of L. fermentum UCO-979C on the
intestinal mucosa.
MATERIALS AND METHODS
Microorganisms
Lactobacillus fermentum UCO-979C was obtained from
the Bacterial Pathogenicity Laboratory culture collection at
University of Concepción (Concepcion, Chile) (20, 21). L.
fermentum CRL973 was obtained from the CERELA culture
collection (Tucuman, Argentina). Lactobacilli strains were
activated from frozen stock and cultured in Mann-Rogosa
Sharpe Agar (MRS Difco) at 37◦C. After 24 h incubation, a single
colony was transferred to MRS broth (MRS Difco) and cultured
at 37◦C for 24 h. Then, bacterial cells were washed three times
with phosphate buffered saline (PBS) and adjusted to appropriate
concentrations for the in vitro and in vivo experiments.
Enterotoxigenic Escherichia coli (ETEC) strain 987P (O9: H-:
987 pilus+: heat stable toxin+) was obtained from the National
Institute of Animal Health (Tsukuba, Japan) (24–26). ETEC cells
were grown in blood agar (5% sheep blood) for 24 h at 37◦C
and transferred to tryptic soy broth (TSB; Becton, Dickinson
and Company, USA) and cultured 20 h at 37◦C with shaking.
After incubation, the subcultures of bacteria were centrifuged
at 5,000 × g for 10min at 4◦C and washed with PBS (pH 7.2).
Finally, ETEC cells were heat killed at 100◦C for 15min and
then washed with PBS. Heat-stable ETEC pathogen associated
molecular patterns (PAMPs) were suspended in DMEM for the
experimental challenge.
Sacharomyces boulardi was obtained from commercial
lyophilized preparation (Floratil—Argentina). The yeast
suspensions were prepared in PBS and heat inactivated during
15min in 100◦C water bath and adjusted to 107 cells/ml for ex
vivo phagocytosis assay.
Porcine Intestinal Epitheliocytes
Porcine intestinal epitheliocytes (PIE cells) are non-transformed
intestinal cultured cells derived from intestinal epithelia isolated
from an unsuckled neonatal swine. When PIE cells are cultured,
they assumed a monolayer, cobblestone, and epithelial-like
morphology, with close contact between cells (24). PIE cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Corporation, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum FCS (Hyclone, Logan, USA), 100mg/ml
penicillin, and 100 U/ml streptomycin at 37◦C in an atmosphere
of 5% CO2. PIE cells grow rapidly and are well adapted to culture
conditions even without transformation or immortalization.
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However, the proliferative ability of PIE cells diminishes after 50
passages in culture. Therefore, we used PIE cells only between
the 20th and 40th passages in these experiments (25, 26). Briefly,
PIE cells were cultured in 250ml flasks (1.0 × 106 cells) for 5
days after reaching 80–90% confluence, changing culture media
every 1–2 days, followed by subculturing in 24 well flasks for
immunostimulation assays as described below.
Immunomodulatory Assay in PIE Cells
Lactobacilli were re-suspended in DMEM (10% FCS),
enumerated in a microscope using a Petroff-Hausser counting
chamber, and stored at −80◦C until use. PIE cells were plated
at 3 × 104 cells/well of a 12-well type I collagen-coated plates
(Iwaki, Tokyo, Japan), and cultured for 3 days. After changing
medium, lactobacilli (5 × 108 cells/ml) were added followed by
stirring in microplate mixer and co- cultured for 48 h at 37◦C 5%
CO2 atmosphere. Then, each well was washed vigorously with
medium at least 3 times to eliminate bacteria. Gene expression of
cytokines, chemokines, complement, and coagulation factors as
well as negative regulators of TLR signaling were studied without
any inflammatory challenge (basal levels) or after heat-stable
ETEC PAMPs challenge (5 × 107 cells/ml) for 12 h (25) by using
RT-PCR as described below.
Quantitative Expression Analysis
by RT-PCR
Two-step real-time qPCR was performed to characterize the
expression of selected genes in PIE cells. Total RNA was isolated
from each PIE cell sample using TRIzol reagent (Invitrogen).
RNA purity and concentration were assessed using NanoDropTM
1,000 Spectophotometer. All cDNAs were synthesized using
the PrimeScript RT Reagent kit with the treatment of gDNA
eraser (Takara—Bio, Japan) according to the manufacturer’s
recommendations. Real-time quantitative PCR (qRT-PCR) was
carried out using a 7,300 real-time PCR system (Applied
Biosystems, Warrington, UK) and the Platinum SYBR green
qPCR SuperMix uracil-DNA glycosylase (UDG) with 6-carboxyl-
X-rhodamine (ROX) (Invitrogen). The primers used in this study
were described previously (25–27). The PCR cycling conditions
were 2min at 50◦C, followed by 5min at 95◦C, and then 40
cycles of 15 s at 95◦C, 30 s at 60◦C, and 30 s at 72◦C, followed
by a dissociation stage of 15 s at 95◦C, 1min at 60◦C, 15 s at
95◦C and 15 s at 60◦C. The reaction mixtures contained 2.5 µl
of cDNA and 7.5 µl of master mix, which included the sense
and antisense primers. According to the guidelines for minimum
information for publication of qRT-PCR experiments, β-actin
was used as a housekeeping gene, to normalize cDNA levels
for differences in total cDNA levels in the samples, because
of its high stability across porcine various tissues (28). The
relative index of a cytokine mRNA in PIE cells stimulated
with lactobacilli was calculated as follows: first, the average
cytokine expression levels from at least three samples challenged
with ETEC without prestimulation with lactobacilli were set to
100. Then, relative expressions of cytokines were calculated in
the samples prestimulated with lactobacilli followed by ETEC
challenge (25).
Animals and Feeding Procedures
Female 6–8 weeks old Balb/c mice were obtained from the
closed colony kept at CERELA (Tucuman, Argentina). They
were housed in plastic cages with controlled room temperature
(22 ± 2◦C temperature, 55 ± 2% humidity) and were fed
ad libitum conventional balanced diet. Animal welfare was
ensured by researchers and special trained staff in animal care
and handling at CERELA. Animal health and behavior were
monitored twice a day. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the Guidelines for Animal
Experimentation of CERELA. The CERELA Institutional Animal
Care and Use Committee prospectively approved this research
under the protocol BIOT-CRL-17.
Mice were housed individually during the experiments and
the assays for each parameter studied were performed in 5–
6 mice per group. L. fermentum UCO-979C or CRL973 were
administered to different groups of mice for 2 consecutive days
at a dose of 108 cells/mouse/day in the drinking water (4ml
per mice per day). Bacteria were prepared as described above,
suspended in 5ml of 10% skimmed milk and added to the
drinking water.
In some experiments, 1 day after at the end of the lactobacilli
treatments, mice were challenged with lipopolysaccharide (LPS)
to induce inflammation. Mice received 8 mg/kg of LPS from E.
coli O55:B5 by intraperitoneal injection.
Ex vivo Phagocytosis Assay
Peritoneal macrophages were collected aseptically from mice
as described previously (29, 30). Briefly, after exposing inner
skin, cold PBS containing 10% fetal bovine serum was carefully
injected into peritoneal cavity. The fluid was collected and
macrophages were washed twice with PBS containing bovine
serum albumin (BSA) and adjusted to a concentration of 1
× 106 cells/ml. Phagocytosis was performed using a heat-
killed S. boulardi. Mixtures of opsonized yeasts in mouse
autologous serum (10%) were added to 0.2ml of macrophage
suspension. The mixture was incubated for 30min at 37◦C. The
percentage of phagocytosis was expressed as the percentage of
phagocytizing macrophages in 200 cells counted using an optical
microscope (30, 31).
Nitro Blue Tetrazolium Test (NBT)
The bactericidal activity (oxidative burst) of peritoneal
macrophages was measured using the NBT reduction test
(Sigma-Aldrich, St. Louis, MO, USA) as previously described
(30). Briefly, 200 µl of peritoneal macrophages obtained as
described above were incubated with 120 µl of NBT reagent
and incubated first at 37◦C for 10min and then 10min at room
temperature. NBT was added to each sample and incubated at
37◦C for 20min. In the presence of oxidative metabolites, NBT
(yellow) is reduced to formazan, which forms a blue precipitate.
Smears were prepared and, after staining, the samples were
examined under a light microscope for blue precipitates.
Randomly, 100 cells were counted and the percentage of NBT
positive (+) cells were determined (30, 31).
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Cytokine Concentrations
The concentration of cytokines was determined in blood and
intestinal samples of UCO-979C-tretated and control mice.
Blood samples were obtained through cardiac puncture at the end
of each treatment and collected in heparinized tubes. Intestinal
fluid samples were obtained as the method described previously
(31). Briefly, the small intestine was flushed with 5ml of PBS
and the fluid was centrifuged (10,000 × g, 4◦C for 10min) to
separate particulate material. The supernatant was kept frozen
until use. Tumor necrosis factor α (TNF-α), interferon γ (IFN-γ),
and interleukin 10 (IL-10) concentrations in serum and intestinal
fluid, were measured with commercially available enzyme-linked
immunosorbent assay (ELISA) kits following the manufacturer’s
recommendations (R&D Systems, MN, USA).
Flow Cytometry
Peritoneal macrophages were collected as described above.
Peyer’s patches were collected and mechanically disaggregated. A
single-cell suspension from the Peyer’s patches of eachmouse was
obtained by gently passing the collected tissue through a tissue
strainer with PBS with 2% FCS (FACS buffer). Cell suspensions
were subjected to red blood cells lysis (Tris-ammonium chloride,
BD PharMingen) flowed by counting on a hemacytometer.
Viability of cells was assessed by trypan blue exclusion. Cell
suspensions were pre-incubated with anti-mouse CD32/CD16
monoclonal antibody (Fc block) for 30min at 4◦C. Cells were
incubated with the antibody mixes for 30min at 4◦C and washed
with FACS buffer. The following antibodies from BD Biosciences
were used: FITC-labeled anti-mouse MHC-II, FITC-labeled anti-
mouse CD86, PE-labeled anti-mouse CD11b, PE-labeled anti-
mouse F4/80, PE-labeled anti-mouse Ly6C, PE-labeled anti-
mouse CD24, biotinylated anti-mouse B220, FITC-labeled anti-
mouse CD3, PE-labeled anti-mouse CD8, and biotinylated
anti-mouse CD4 antibodies. Streptavidin-PerCP was used as a
second-step reagent. Flow cytometry was performed using a BD
FACSCaliburTM flow cytometer (BD Biosciences) and data were
analyzed using FlowJo software (TreeStar).
Statistical Analysis
Experiments were performed in triplicate and results expressed as
the mean ± SD. For the comparison of two groups, the Student’s
t-test was used. For the comparison of more than two groups, a
one-way analysis of variance (ANOVA) was performed followed
by and Tukey’s test. In all cases, a level of significance of p < 0.05
was considered.
RESULTS
L. fermentum UCO-979C Modifies
Cytokine Profile in PIE Cells
We first evaluated whether L. fermentum UCO-979C was able to
modify the cytokine expression profile of PIE cells by evaluating
the mRNA levels of IL-6, CXCL8 (IL-8), CXCL5 (AMCF-
II), CXCL9, CXCL10 (IP-10), CXCL11, and CCL8 (MCP1) as
shown in Figure 1. Then, in order to evaluate whether the
immunomodulatory effects of L. fermentum UCO-979C were a
strain specific property, we performed comparative experiments
with the strain of the same species L. fermentum CRL973.
Stimulation of PIE cells with the UCO-979C or CRL973 strains
increased the expression of IL-6 and CXCL9, respectively, while
no differences were found between controls and lactobacilli-
treated PIE cells when the other chemokines were analyzed.
The modulation of cytokines and chemokines was also studied
in the context of inflammation. For this purpose, PIE cells
were treated with lactobacilli and then challenged with heat-
stable ETEC PAMPs that are able to trigger Toll-like receptor
4 (TLR4) activation in this cell line (25, 26). Untreated PIE
cells challenged with ETEC were used as controls. Heat-
stable ETEC PAMPs significantly increased the expression of
all the inflammatory cytokines and chemokines in all the
experimental groups (Figure 1). However, the mRNA expression
levels of IL-6 and CCL8 were significantly higher in lactobacilli-
treated cells. In addition, expression of CXCL8, CXCL10, and
CXCL11 were lower in lactobacilli-treated PIE cells than in
controls. Interestingly, only L. fermentum CRL973 was able to
reduce CXCL5 expression (Figure 1). L. fermentum CRL973
increased CXCL9 expression after ETEC challenge while the
UCO-979C strain reduced the expression of this chemokine
(Figure 1). Our previous immunotranscriptomics studies in PIE
cells revealed that in addition to cytokines and chemokines,
immunomodulatory probiotic strains are able also to modulate
factors from the complement and coagulation systems (27).
Therefore, we evaluated the expressions of C1S, C1R, C3, CFB,
and F3 in PIE cells under inflammatory and non-inflammatory
conditions (Figure 2). No significant expression differences were
observed for these factors when control and lactobacilli-treated
PIE cells were compared. Challenge with heat-stable ETEC
PAMPs increased C1S, C1R, C3, CFB, and F3 expressions in all
the experimental groups. L. fermentum UCO-979C-treated PIE
cells had significantly lower levels of C1S and C3, and higher
levels of C1R and CFB expression as compared to controls. While
L. fermentum CRL973-treated PIE cells exhibited significantly
lower levels of C1S, C1R, and CFB than controls (Figure 2).
No significant differences were observed in F3 expression when
control and lactobacilli-treated PIE cells were compared.
L. fermentum UCO-979C Modifies Negative
Regulators of TLR4 Signaling in PIE Cells
We next evaluated whether L. fermentum UCO-979C was
able to modify the expression of negative regulators of TLR4
signaling in PIE cells (Figure 3). No significant differences were
observed in the expression of A20, Bcl3, MKP-1, and SIGIRR
when untreated control, and lactobacilli-treated PIE cells were
compared. Both, UCO-979C and CRL973 strains were able to
reduce the expression of Tollip in PIE cells, while L. fermentum
CRL973 increased IRAK-M expression. Challenge with heat-
stable ETEC PAMPs increased A20, Bcl3, MKP-1, IRAK-M, and
SIGIRR in all the experimental groups. L. fermentum UCO-
979C-treated PIE cells had significantly lower levels of MKP-
1 and Tollip, and higher levels of Bcl3 than controls, while L.
fermentum CRL973 showed significantly lower levels of A20 and
IRAK-M expressions than controls (Figure 3). Both lactobacilli
improved the expression of SIGIRR.
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FIGURE 1 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on the expression of cytokines and chemokines in porcine intestinal epithelial
(PIE) cells. PIE cells were pre-treated with UCO-979C or CRL973 strains for 48 h and then stimulated with heat-stable Enterotoxigenic Escherichia coli (ETEC)
pathogen-associated molecular patterns (PAMPs). The expression of cytokines (IL-6) and chemokines (CXCL5, CXCL8, CXCL9, CXCL10, CXCL11, and CCL8) were
studied at 48 h after lactobacilli stimulation (basal) or at 12 h after heat-stable ETEC PAMPs challenge. The results represent three independent experiments. Results
are expressed as mean ± SD. Significantly different from control PIE cells at the same time point *(P < 0.05), **(P < 0.01).
L. fermentum UCO-979C Modulates
Intestinal Immunity in vivo
Taking into consideration that the capacity of increasing IgA
production in the gut, and stimulating macrophages and
dendritic cells are amongst the beneficial effects of lactobacilli
on the immune system (30, 32), we next aimed to evaluate in
vivo the ability of L. fermentum UCO-979C to modulate those
parameters. As shown in Figure 4, administration of the UCO-
979C strain significantly increased the phagocytic activity of
peritoneal macrophages while this effect was absent in the case
of CRL973 strain. In order to study the activation of respiratory
burst in peritoneal macrophages, we used the NBT method
as described previously (30). Both, UCO-979C and CRL973
treatments were equally effective for increasing the percentage of
NBT+ cells in the population of macrophages obtained from the
peritoneal cavity (Figure 4). In addition, mice orally treated with
the UCO-979C strain had significantly higher levels of intestinal
IgA antibodies than control animals while L. fermentum CRL973
did not induce significant changes (Figure 4). It has established
that the in vivo immunomodulatory abilities of probiotic bacteria
are in part attributable to altered production of cytokines that
play pivotal roles in coordinating the immune function. Then, we
analyzed the concentrations of cytokines in intestinal fluid and
serum obtained from lactobacilli-treated mice, to determine the
local and systemic effects induced by both L. fermentum strains
(Figure 5). No significant differences were observed between
lactobacilli-treated and control mice when intestinal and serum
TNF-α concentrations were analyzed. Intestinal IFN-γ protein
level was augmented by both L. fermentum UCO-979C and
CRL973 while no differences were observed for serum IFN-
γ between the groups. In addition, L. fermentum UCO-979C
significantly increased intestinal and serum IL-10 levels, an
effect that was not observed for the CRL973 strain (Figure 5).
We also evaluated the levels of these three cytokines: TNF-α,
IFN-γ, and IL-10, in mice after the intraperitoneal challenge
with LPS (Figure 6). The inflammatory stimulus increased the
concentration of intestinal and serum TNF-α, and IFN-γ in all
experimental groups. However, TNF-α level was significantly
lower in L. fermentum UCO-979C-treated mice when compared
with those receiving the CRL973 strain or controls. In addition,
both lactobacilli augmented the production of intestinal IFN-
γ after the challenge with LPS while only UCO-979C strain
increased the levels of this cytokine in serum (Figure 6). LPS
challenge also increased IL-10 both in intestinal fluid and serum
of mice; however, the levels of this immunoregulatory cytokine
were significantly higher in L. fermentum UCO-979C-treated
mice when compared with those receiving the CRL973 strain or
controls (Figure 6).
L. fermentum UCO-979C Modulates
Intestinal Immune Cell Populations in vivo
We aimed to evaluate the effect of L. fermentum UCO-
979C on peritoneal and intestinal immune cell populations in
order to further characterize the immunomodulatory activity
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FIGURE 2 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on the expression of factors from the complement and coagulation systems in
porcine intestinal epithelial (PIE) cells. PIE cells were pre-treated with UCO-979C or CRL973 strains for 48 h and then stimulated with heat-stable Enterotoxigenic
Escherichia coli (ETEC) pathogen-associated molecular patterns (PAMPs). The expression of factors from the complement (C1S, C1R, C3, and CFB) and coagulation
(F3) systems were studied at 48 h after lactobacilli stimulation (basal) or at 12 h after heat-stable ETEC PAMPs challenge. The results represent three independent
experiments. Results are expressed as mean ± SD. Significantly different from control PIE cells at the same time point *(P < 0.05), **(P < 0.01).
of this strain. In the peritoneal fluid, resident macrophages
(F4/80+ cells) as well as inflammatory monocyte and neutrophils
(Ly6C/Gr1+ cells) were studied by flow cytometry. As shown
in Figure 7, the percentage of peritoneal F4/80+ macrophages
as well as activated macrophages (F4/80+MCH-II+ cells)
was increased in UCO-979C-treated mice when compared
to controls, while no significant differences between the
groups were observed when Ly6C/Gr1+ and Ly6C/Gr1+MHC-
II+ cells were studied. Antigen presenting cells were also
analyzed in Peyer’s patches of mice (Figure 8). No significant
differences were observed between UCO-979C-tretaed and
control mice when CD11b+ (dendritic cells) or F4/80+
(macrophages) cells from Peyer’s patches were evaluated.
In addition, there were no differences between the groups
in activated CD11b+CD86+ dendritic cells; however, the
percentage of activated F4/80+CD86+ macrophages were
significantly higher in L. fermentum UCO-979C-treated mice
when compared with controls (Figure 8). Finally, B and T
cells populations in Peyer’s patches were studied (Figure 9). L.
fermentum UCO-979C treatment improved the proportions of
both CD3+CD4+ and CD3+CD8+ T cells when compared to
controls. No differences between the groups were detected in the
population of B220high cells; however, the proportion of B220low
and B220+CD24high cells (immature B cells) from Peyer’s patches
were significantly reduced in L. fermentum UCO-979C-treated
mice when compared with controls (Figure 9). In addition,
B220+CD24low population (mature B cells) from Peyer’s patches
were higher in L. fermentum UCO-979C-treated mice than that
of controls.
DISCUSSION
We previously reported that L. fermentumUCO-979Cmodulates
the innate immune response in human gastric epithelial cells and
macrophages, and improves protection againstH. pylori infection
(23). Here, we demonstrated for the first time that the UCO-979C
strain is also capable ofmodulating the intestinal immune system.
The recent scientific advances in the biology of IECs have
dramatically expanded our appreciation of their immunological
functions. IECs establish an interconnected network with
underlying immune cells and with the microbiota on their
surface, and these complex interactions between intestinal cells
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FIGURE 3 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on the expression of negative regulators of the Toll-like receptor (TLR) signaling
pathway in porcine intestinal epithelial (PIE) cells. PIE cells were pre-treated with UCO-979C or CRL973 strains for 48 h and then stimulated with heat-stable
Enterotoxigenic Escherichia coli (ETEC) pathogen-associated molecular patterns (PAMPs). The expression of negative regulators of the TLR signaling pathway were
studied at 48 h after lactobacilli stimulation (basal) or at 12 h after heat-stable ETEC PAMPs challenge. The results represent three independent experiments. Results
are expressed as mean ± SD. Significantly different from control PIE cells at the same time point *(P < 0.05), **(P < 0.01).
FIGURE 4 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on peritoneal macrophages activities and intestinal IgA production in adult
immunocompetent mice. L. fermentum UCO-979C or CRL973 were administered to different groups of mice for 2 consecutive days at a dose of 108
cells/mouse/day. Untreated mice were used as controls. One day after the last lactobacilli administration, phagocytic and bactericidal (oxidative burst) activities of
peritoneal macrophages, and intestinal IgA concentrations were determined. The results represent three independent experiments. Results are expressed as mean ±
SD. Significantly different from control mice *(P < 0.05).
and microorganisms significantly influence the host defense
against threats from the intestinal lumen (33, 34). IECs play
crucial roles in the recognition of microorganisms in both
homeostatic and pathologic conditions through the expression
of innate receptors including the TLRs. Signaling through
TLR by pathogens in IECs initiates signaling cascades that
culminates in the expression and secretion of various cytokines,
chemokines, and other inflammatory factors which signal and
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FIGURE 5 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on intestinal and serum cytokines of adult immunocompetent mice. L.
fermentum UCO-979C or CRL973 were administered to different groups of mice for 2 consecutive days at a dose of 108 cells/mouse/day. Untreated mice were used
as controls. One day after the last lactobacilli administration, the concentrations of TNF-α, IFN-γ, and IL-10 in intestinal fluid and serum were determined. The results
represent three independent experiments. Results are expressed as mean ± SD. Significantly different from control mice *(P < 0.05).
FIGURE 6 | Effect of Lactobacillus fermentum UCO-979C and L. fermentum CRL973 on intestinal and serum cytokines of adult immunocompetent mice after
lipopolysaccharide (LPS) challenge. L. fermentum UCO-979C or CRL973 were administered to different groups of mice for 2 consecutive days at a dose of 108
cells/mouse/day. Untreated mice were used as controls. Lactobacilli-treated and control mice were challenged with LPS by intraperitoneal injection. One day after the
challenge, the concentrations of TNF-α, IFN-γ, and IL-10 in intestinal fluid and serum were determined by ELISA. The results represent three independent
experiments. Results are expressed as mean ± SD. Significantly different from control mice *(P < 0.05).
prime underlying immune cells (33, 34). It was also reported
that commensal and probiotic bacteria are recognized by
IECs through innate receptors (13). Moreover, immunobiotic
bacteria are able to influence TLR signaling induced by
pathogens in IECs and therefore, to differentially modulate
immune responses (13).
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FIGURE 7 | Effect of Lactobacillus fermentum UCO-979C on peritoneal phagocytic cells of adult immunocompetent mice. L. fermentum UCO-979C was
administered to mice for 2 consecutive days at a dose of 108 cells/mouse/day. Untreated mice were used as controls. One day after the last lactobacilli
administration, peritoneal phagocytes were evaluated by flow cytometry. The results represent three independent experiments. Results are expressed as mean ± SD.
Significantly different from control mice *(P < 0.05).
We have previously used PIE cells to evaluate the effect
of immunobiotic bacteria on TLR signaling induced by
PAMPs. We demonstrated that stimulation of PIE cells with
heat-stable ETEC PAMPs activates NF-kB and induces the
phosphorylation of MAPK-ERK, MAPK-p38, and MAPK-JNK
leading to the production of inflammatory cytokines (25).
Later, by performing transcriptomic studies we corroborated
these findings by demonstrating that activation of NF-kB and
MAPK pathways in PIE cells results in an increased expression
of several chemokines including CCL4, CCL5, CCL8, CCL20,
CXCL2, CXCL5, CXCL9, CXCL10, CXCL11, CSF2, as well as
complement and coagulation factors (27). Interestingly, we have
also demonstrated that prestimulation of PIE cells with the
immunobiotic strain Lactobacillus jensenii TL2937 differentially
modulated the expression of inflammatory factors produced
in response to heat-stable ETEC PAMPs challenge (25, 27)
(Figure 10A). The upregulation of the negative regulators MKP-
1, A20, and Bcl-3 induced by the TL2937 strain in PIE cells
was found to be related to the different immunotrascriptomic
response after heat-stable ETEC PAMPs challenge (25, 27). Here,
we performed similar experiments in order to evaluate the
immunomodulatory effects of L. fermentum UCO-979C in IECs.
Our results showed that the prestimulation of PIE cells with
the UCO-979C strain differentially modulated the expression of
inflammatory factors induced by the heat-stable ETEC PAMPs
challenge (Figure 10A). The changes induced by L. fermentum
UCO-979C were distinct from those previously observed for the
immunobiotic strain TL2937. While L. jensenii TL2937 induced
a clear and remarkable anti-inflammatory effect (25, 27), L.
fermentum UCO-979C produced a stimulant/anti-inflammatory
mixed effect (Figure 10A). Though some inflammatory factors
such as CXCL8, CXCL9, CXCL10, CXCL11, C1S, and C3 were
significantly reduced in UCO-979C-treated PIE cells; others like
IL-6, CCL8, C1R, and CFB were upregulated.
The up- and down-regulation of inflammatory factors
correlated with the changes induced by L. fermentumUCO-979C
on the expression of negative regulators of TLR4 signaling as
evidenced by the augmented expression of SIGIRR and Bcl3,
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FIGURE 8 | Effect of Lactobacillus fermentum UCO-979C on Peyer’s patches phagocytic cells of adult immunocompetent mice. L. fermentum UCO-979C was
administered to mice for 2 consecutive days at a dose of 108 cells/mouse/day. Untreated mice were used as controls. One day after the last lactobacilli
administration, Peyer’s patches phagocytes were evaluated by flow cytometry. The results represent three independent experiments. Results are expressed as mean
± SD. Significantly different from control mice *(P < 0.05).
and the reduced expression of Tollip and MKP-1 (Figure 10A).
The intestinal innate immune system needs to keep a balance
in TLR activation to confer protection and avoid exaggerated
inflammatory responses. Several levels of negative regulation
have been described for TLR activation including the expression
of membrane bound suppressors and intracellular inhibitors (13,
35). In this regard, some probiotic strains have shown to reduce
TLR negative regulators and control the inflammation (36).
Lactobacillus amylovorus DSM 16698 was reported to diminish
IL-1β and IL-8 levels in IECs infected with ETECK88 through the
modulation of the negative regulators Tollip and IRAK-M (37).
ETEC K88-challenged pigs exhibited a reduced inflammatory
response after L. acidophilus administration and this effect was
associated with an increased expression of splenic Tollip, IRAK-
M, A20, and Bcl-3 (38). In addition, L. plantarum CGMCC1258
increased SIGIRR, Bcl3, and MKP-1 gene expressions in porcine
IECs challenged with ETEC K88 ameliorating the production of
IL-8 and TNF-α (39).
The stimulating/anti-inflammatory mixed effect of L.
fermentum UCO-979C in PIE cells contrast with our previous
findings in AGS cells (23). We demonstrated that L. fermentum
UCO-979C significantly diminished the production of IL-8,
TNF-α, IL-1β, IL-6, and MCP-1 in AGS cells challenged with
H. pylori. Of interest, in addition to its capacity to reduce
the production of pro-inflammatory factors we observed that
L. fermentum UCO-979C was also capable to improve the
production of TGF-β in H. pylori-infected AGS cells. These
findings indicate that it is of great importance to characterize
the immunomodulatory properties of the probiotic strains in
different cellular models since it is not possible to extrapolate
their effect in one mucosal tissue to another.
Several studies have reported the beneficial effects of
immunobiotics on intestinal health and those studies have shown
that the most remarkable effect of immunobiotics on intestinal
cytokine dynamics is the increase of TNF-α, IFN-γ, and the
regulatory cytokine IL-10 (30, 40). We have shown consistently
that the oral administration of immunobiotic strains including
L. casei CRL431, L. plantarum CRL1506, and L. rhamnosus
CRL1505 improves the production of TNF-α, IFN-γ, and IL-
10 in the gut (30, 31, 41). Moreover, we demonstrated that oral
administration of the immunostimulatory strain L. rhamnosus
CRL1505 to mice improved the activation of intestinal and
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FIGURE 9 | Effect of Lactobacillus fermentum UCO-979C on Peyer’s patches lymphocytes of adult immunocompetent mice. L. fermentum UCO-979C was
administered to mice for 2 consecutive days at a dose of 108 cells/mouse/day. Untreated mice were used as controls. One day after the last lactobacilli
administration, Peyer’s patches T and B cells were evaluated by flow cytometry. The results represent three independent experiments. Results are expressed as mean
± SD. Significantly different from control mice *(P < 0.05).
FIGURE 10 | Proposed mechanisms for the immunomodulatory activity of Lactobacillus fermentum UCO-979C on intestinal mucosa. (A) Effect of L. fermentum
UCO-979C on intestinal epithelial cells and modulation of the inflammatory response triggered by heat-stable Enterotoxigenic Escherichia coli (ETEC)
pathogen-associated molecular patterns (PAMPs). The immunomodulatory activity of the UCO-979C strain is compared with the activity of the probiotic strain
Lactobacillus jensenii TL2937 and with L. fermentum CRL973. (B) Effect of L. fermentum UCO-979C on intestinal immune cells. The immunomodulatory activity of the
UCO-979C strain is compared with the activity of the probiotic strain Lactobacillus rhamnosus CRL1505.
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peritoneal macrophages as well as Peyer’s patches CD4+IFN-γ+
T cells (30, 31, 41). In the present study, the oral administration of
L. fermentum UCO-979C significantly improved the production
of IFN-γ, and IL-10 but not the TNF-α. The UCO-979C strain
stimulated intestinal and peritoneal macrophages and improved
Peyer’s patches CD4+ T cells, although the effects were less
pronounced than those previously observed for the CRL1505
strain (Figure 10B). These results indicate that L. fermentum
UCO-979C would be capable of stimulating CD4+ T cells in the
gut, increasing IFN-γ production and consequently stimulating
the macrophages. In fact, peritoneal macrophages of UCO-979C-
treated mice had improved levels of parameters that are involved
in several fundamental steps of the phagocytic process including
attachment to surface and internalization of S. boulardii as
well as their microbicidal activity through oxidative burst. We
previously reported that L. fermentum UCO-979C modulated
cytokine production in THP-1 macrophages challenged either
with H. pylori or LPS (23). The UCO-979C strain was able
to reduce the production of TNF-α, and to improve IFN-
γ levels in challenged THP-1 macrophages. In addition, we
demonstrated that L. fermentum UCO-979C increased the
production of IL-10 in THP-1 macrophages challenged with
H. pylori (23). Our previous results and those obtained in this
work therefore suggest that the UCO-979C strain could exert
an immunomodulatory effect on macrophages acting directly on
them or indirectly through the cytokines produced by IECs or
other immune cells.
Another effect that has been consistently described for
probiotics on the intestinal immune system is their ability
to improve secretory IgA production, which is supported in
most cases by an improved production of factors released by
IECs. Cytokines produced by IECs such as IL-6 are capable
of promoting the switch from IgM to IgA expression in B
cells (31, 40). It is considered that approximately 80% of
antibody-secreting plasma cells in the human body are located
in the gut. Intestinal antibody-secreting plasma cells produce
secretory IgA that plays an important protective role against
pathogens and toxins through a variety of non-inflammatory
activities that increase their clearance, and prevent their access
to the intestinal epithelium (42). Dimeric IgA also neutralize
endocytosed LPS in intestinal epithelium, preventing NF-κB
activation (43). IgA-producing B cells can be generated by
both T cell-dependent and -independent processes (44). T
cell-dependent responses usually occur in germinal centers in
lymphoid tissues such as the Peyer’s patches and mesenteric
lymph nodes. In such structures, B cells undergo several
rounds of activation and maturation that are supported by
follicular T cells that express co-stimulatory molecules and
cytokines. In T-independent responses, which occur outside
germinal centers, B cells are activated by IECs and innate
immune cells to produce polyreactive IgA (45). The T-
independent IgA production is induced by and influences the
composition of indigenous members of the microbiota (42).
In addition, improvement of T-independent IgA induction
supported by TGF-β, IL-4, IL-2, IL-6, and IL-10 was also
demonstrated for immunobiotic strains including L. casei
CRL431 (40), L. rhamnosus GG (46), and L. rhamnosus
CRL1505 (31). In this work, we have observed that the
oral administration of the L. fermentum UCO-979C improves
intestinal IL-6, reduces immature B220+CD24high B cells from
Peyer’s patches, enhances mature B B220+CD24low cells and
significantly increases intestinal IgA, although these effects were
less pronounced than those observed for the CRL1505 strain
(Figure 10B).
Interestingly, L. fermentum CRL973 showed a modest
immunomodulatory effect in vitro (Figure 10A). The CRL973
strain increased the expression of SIGIRR and reduced the
expression of the negative regulators A20 and IRAK-M in PIE
cells after heat-stable ETEC PAMPs challenge. However, the in
vivo studies in mice demonstrated that the CRL973 strain was not
able to exert an immunomodulatory effect since no improvement
of intestinal cytokines, IgA production, or activation of peritoneal
macrophages was observed in the CRL973-treated mice. These
findings are of importance since they confirm the general
knowledge that the immunobiotic properties are dependent
on each specific strain. Moreover, results of this study open
up an interesting possibility for future research since cellular,
molecular, and genomic comparative studies between both
UCO-979C and CRL973 strains could help to understand the
immunological mechanisms involved in the beneficial effects of
L. fermentum UCO-979.
We have demonstrated that L. fermentum UCO-979C is able
to differentially modulate the cytokine response of human gastric
epithelial cells and macrophages, and to improve protection
against H. pylori infection in vitro (23). The UCO-979C strain
is also capable to modulate the immune response of IECs
triggered by heat-stable ETEC PAMPs challenge. Notably, we
demonstrated here for the first time that L. fermentum UCO-
979C is able to exert its immunomodulatory effect in the
intestinal mucosa in vivo. Therefore, L. fermentum UCO-
979C has several characteristics for making it an excellent
candidate for the development of immunobiotic functional
foods to prevent infections by gastric and intestinal pathogens.
The in vivo evaluation of the ability of the UCO-979C
strain to beneficially influence the immune response and
improve protection against H. pylori and other intestinal
pathogenic Gram-negative bacteria is an interesting point for
further research.
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